• 1
    De Nardo GL, O'Donnell RT, Kroger LA, Richman CM, Goldstein DS, Shen S, et al. Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res 1999; 5(Suppl): 3219s-3223s.
  • 2
    De Nardo SJ, Kroger LA, De Nardo GL. A new era for radiolabeled antibodies in cancer. Curr Opin Immunol 1999; 11: 5639.
  • 3
    Potamianos S, Varvarigou AD, and Archimandritis SC. Radioimmunoscintigraphy and radioimmunotherapy in cancer: Principles and application. Anticancer Res 2000;20: 92548.
  • 4
    Pedley R, Boden J, Boden R, Dale R, Begent R. Comparative radioimmunotherapy using intact or F(ab′)2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer 1993; 68: 6973.
  • 5
    Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 34028.
  • 6
    Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996; 2: 97984.
  • 7
    Garkavij M, Tennvall J, Strand SE, Nilsson R, Lindgren L, Chen J, et al. Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept: evaluation of a new method. Acta Oncol 1996; 35: 30912.
  • 8
    Begent RH, Bagshawe DK, Pedley RB, Searle F, Ledermann JA, Green AJ, et al. Use of second antibody in radioimmunotherapy. Natl Cancer Inst Monogr 1987; 3: 5961.
  • 9
    Ullén A, Sandström P, Riklund Åhlström K, Sundström B, Nilsson B, Ärlestig L and Stigbrand T. Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor:nontumor ratio in experimental radioimmunotargeting. Cancer Res 1995; 55(Suppl):5868s5873s.
  • 10
    Casey JL, King DJ, Pedley RB, Boden JA, Boden R, Chaplin LC, et al. Clearance of yttrium-90–labelled anti-tumor antibodies with antibodies raised against the 12N4 DOTA macrocycle. Br J Cancer 1998; 78: 130712.
  • 11
    Ullé A, Riklund Åhlström K, Hietala S-O, Nilsson B, Ärlestig L, Stigbrand T. Secondary antibodies as tools to improve tumor to nontumor ratio at radioimmunolocalisation and radioimmunotherapy. Acta Oncol 1996;35: 2815.
  • 12
    Johansson A, Sandström P, Ullén A, Behravan G, Erlandsson A, Levi M, et al. Epitope specificity of the monoclonal anticytokeratin antibody TS1. Cancer Res 1999; 59: 4851.
  • 13
    Riklund Åhlström K, Ullén A, Makiya R, Sundström B, Thornell L–E, Stigbrand T. Radioimmunotherapy of HeLa cell tumors in nude mice by a combination of iodine-131–labelled monoclonal antibodies against placental alkaline phosphatase and cytokeratin. Tumor Targeting 1995;1: 23944.
  • 14
    Ullén A, Sandström P, Rossi Norrlund R, Rathsman S, Johansson L, Riklund Åhlström K, et al. Dosimetry of fractionated administration of 125I-labeled antibody at experimental radioimmunotargeting. Cancer 1997; 80(Suppl): 25102518.
  • 15
    Sundström B, Nathrath WBJ, Stigbrand T. Diversity in immunoreactivity of tumor-derived cytokeratin monoclonal antibodies. J Histochem Cytochem 1989; 37: 184554.
  • 16
    Roux KH. Immunoelectron microscopy of idiotype–anti- idiotype complexes. Methods Enzymol 1989; 178: 13044.
  • 17
    Roux KH. Negative-stain immunoelectron-microscopic analysis of small macromolecules of immunologic significance. Methods 1996; 10: 24756.
  • 18
    Sharkey R, Primus J, Goldenberg D. Second antibody clearance of radiolabeled antibody in cancer radioimmunodetection. Proc Natl Acad Sci U S A 1984; 8128436.
  • 19
    Roux KH, Strelets L, Brekke OH, Sandlie I, Michaelsen TE. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE and IgA2 to form samll immune complexes: a role for flexibility and geometry. J Immunol 1998; 161: 408390.
  • 20
    Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol 1997; 159: 337282.
  • 21
    Schumaker VN, Phillips ML, Hanson DC. Dynamic aspects of antibody structure. Mol Immunol 1991; 28: 134760.
  • 22
    Murphy RM, Chamberlin RA, Schurtenberger P, Colton CK, Yarmush ML. Size and structure of antigen-antibody complexes: thermodynamic parameters. Biochemistry 1990; 29: 1088999.
  • 23
    Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 1988; 7: 198994.
  • 24
    Phillips ML, Oi VT, Schumaker VN. Electron microscopic study of ring-shaped, bivalent hapten, bivalent antidansyl monoclonal antibody complexes with identical variable domains but IgG1, IgG2a and IgG2b constant domains. Mol Immunol 1990; 27: 18190.
  • 25
    Roux KH, Greenspan NS. Monitoring the formation of soluble immune complexes composed of idiotype and anti-idiotype antibodies by electron microscopy. Mol Immunol 1994; 31: 599606.
  • 26
    Moyle WR, Lin C, Corson RL, Ehrlich PH. Quantitative explanation for increased affinity shown by mixtures of monoclonal antibodies: importance of a circular complex. Mol Immunol 1983; 20: 43952.
  • 27
    Chan LM, Cathou RE. The role of the inter-heavy chain disulfide bond in modulating the flexibility of the immunoglobulin G antibody. J Mol Biol 1977; 112: 6536.
  • 28
    Skogh T, Blomhoff R, Eskild W, Berg T. Hepatic uptake of circulating IgG immune complexes. Immunology 1985; 55: 585.
  • 29
    Kosugi I, Muro H, Shirasawa H, Ito I. Endocytosis of soluble IgG immune complex and its transport to lysosomes in hepatic sinusoidal endothelial cells. J Hepatol 1992; 16: 10614.
  • 30
    Sharkey RM, Blumenthal RD, Goldenberg DM. Anti-antibody enhancement of tumor imaging. Cancer Treat Res 1990; 51: 43355.